{"pmid":32447630,"title":"COVID-19 and the nervous system.","text":["COVID-19 and the nervous system.","A pandemic due to novel coronavirus arose in mid-December 2019 in Wuhan, China, and in 3 months' time swept the world. The disease has been referred to as COVID-19, and the causative agent has been labelled SARS-CoV-2 due to its genetic similarities to the virus (SARS-CoV-1) responsible for the severe acute respiratory syndrome (SARS) epidemic nearly 20 years earlier. The spike proteins of both viruses dictate tissue tropism using the angiotensin-converting enzyme type 2 (ACE-2) receptor to bind to cells. The ACE-2 receptor can be found in nervous system tissue and endothelial cells among the tissues of many other organs.Neurological complications have been observed with COVID-19. Myalgia and headache are relatively common, but serious neurological disease appears to be rare. No part of the neuraxis is spared. The neurological disorders occurring with COVID-19 may have many pathophysiological underpinnings. Some appear to be the consequence of direct viral invasion of the nervous system tissue, others arise as a postviral autoimmune process, and still others are the result of metabolic and systemic complications due to the associated critical illness. This review addresses the preliminary observations regarding the neurological disorders reported with COVID-19 to date and describes some of the disorders that are anticipated from prior experience with similar coronaviruses.","J Neurovirol","Berger, Joseph R","32447630"],"abstract":["A pandemic due to novel coronavirus arose in mid-December 2019 in Wuhan, China, and in 3 months' time swept the world. The disease has been referred to as COVID-19, and the causative agent has been labelled SARS-CoV-2 due to its genetic similarities to the virus (SARS-CoV-1) responsible for the severe acute respiratory syndrome (SARS) epidemic nearly 20 years earlier. The spike proteins of both viruses dictate tissue tropism using the angiotensin-converting enzyme type 2 (ACE-2) receptor to bind to cells. The ACE-2 receptor can be found in nervous system tissue and endothelial cells among the tissues of many other organs.Neurological complications have been observed with COVID-19. Myalgia and headache are relatively common, but serious neurological disease appears to be rare. No part of the neuraxis is spared. The neurological disorders occurring with COVID-19 may have many pathophysiological underpinnings. Some appear to be the consequence of direct viral invasion of the nervous system tissue, others arise as a postviral autoimmune process, and still others are the result of metabolic and systemic complications due to the associated critical illness. This review addresses the preliminary observations regarding the neurological disorders reported with COVID-19 to date and describes some of the disorders that are anticipated from prior experience with similar coronaviruses."],"journal":"J Neurovirol","authors":["Berger, Joseph R"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32447630","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s13365-020-00840-5","keywords":["covid-19","coronavirus","encephalitis","meningitis","myositis","neurological complications","sars-cov-2","stroke"],"locations":["Wuhan","China","Myalgia"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1667698385846534144,"score":9.490897,"similar":[{"pmid":32378030,"pmcid":"PMC7202903","title":"COVID-19-Related Stroke.","text":["COVID-19-Related Stroke.","The COVID-19 pandemic is associated with neurological symptoms and complications including stroke. There is hypercoagulability associated with COVID-19 that is likely a \"sepsis-induced coagulopathy\" and may predispose to stroke. The SARS-CoV-2 virus binds to angiotensin-converting enzyme 2 (ACE2) present on brain endothelial and smooth muscle cells. ACE2 is a key part of the renin angiotensin system (RAS) and a counterbalance to angiotensin-converting enzyme 1 (ACE1) and angiotensin II. Angiotensin II is proinflammatory, is vasoconstrictive, and promotes organ damage. Depletion of ACE2 by SARS-CoV-2 may tip the balance in favor of the \"harmful\" ACE1/angiotensin II axis and promote tissue injury including stroke. There is a rationale to continue to treat with tissue plasminogen activator for COVID-19-related stroke and low molecular weight heparinoids may reduce thrombosis and mortality in sepsis-induced coagulopathy.","Transl Stroke Res","Hess, David C","Eldahshan, Wael","Rutkowski, Elizabeth","32378030"],"abstract":["The COVID-19 pandemic is associated with neurological symptoms and complications including stroke. There is hypercoagulability associated with COVID-19 that is likely a \"sepsis-induced coagulopathy\" and may predispose to stroke. The SARS-CoV-2 virus binds to angiotensin-converting enzyme 2 (ACE2) present on brain endothelial and smooth muscle cells. ACE2 is a key part of the renin angiotensin system (RAS) and a counterbalance to angiotensin-converting enzyme 1 (ACE1) and angiotensin II. Angiotensin II is proinflammatory, is vasoconstrictive, and promotes organ damage. Depletion of ACE2 by SARS-CoV-2 may tip the balance in favor of the \"harmful\" ACE1/angiotensin II axis and promote tissue injury including stroke. There is a rationale to continue to treat with tissue plasminogen activator for COVID-19-related stroke and low molecular weight heparinoids may reduce thrombosis and mortality in sepsis-induced coagulopathy."],"journal":"Transl Stroke Res","authors":["Hess, David C","Eldahshan, Wael","Rutkowski, Elizabeth"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32378030","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s12975-020-00818-9","keywords":["angiotensin-converting enzyme 2 (ace2)","covid-19","coagulopathy","sars-cov-2","sepsis","stroke"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666597097428746242,"score":257.1843},{"pmid":32333487,"title":"Does SARS-Cov-2 invade the brain? Translational lessons from animal models.","text":["Does SARS-Cov-2 invade the brain? Translational lessons from animal models.","The current coronavirus disease (COVID-19) outbreak, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has raised the possibility of potential neurotropic properties of this virus. Indeed, neurological sequelae of SARS-CoV-2 infection have already been reported and highlight the relevance of considering the neurological impact of coronavirus from a translational perspective. Animal models of SARS and Middle East respiratory syndrome (MERS), caused by structurally similar coronaviruses during the 2002 and 2012 epidemics, have provided valuable data on nervous system involvement by coronaviruses and the potential for CNS spread of SARS-CoV-2. One key finding that may unify these pathogens is that all require angiotensin-converting enzyme 2 (ACE2) as a cell entry receptor. The CoV spike glycoprotein, by which SARS_CoV-2 binds to cell membranes, binds ACE2 with a higher affinity compared to SARS-CoV. The expression of this receptor in neurons and endothelial cells hints that SARS-CoV-2 may have higher neuroinvasive potential compared to previous coronaviruses. Yet, how such invasiveness might contribute to respiratory failure or cause direct neurological damage remains to be determined. Both direct and indirect mechanisms may be of relevance. Clinical heterogeneity potentially driven by differential host immune-mediated responses will require extensive investigation. Development of disease models to anticipate emerging neurological complications and to explore mechanisms of direct or immune-mediated pathogenicity in the short- and medium- term is therefore of great importance. In this brief review, we describe the current knowledge from models of previous coronavirus infections and discuss their potential relevance to COVID-19.","Eur J Neurol","Natoli, Silvia","Oliveira, Vanessa","Calabresi, Paolo","Maia, Luis F","Pisani, Antonio","32333487"],"abstract":["The current coronavirus disease (COVID-19) outbreak, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has raised the possibility of potential neurotropic properties of this virus. Indeed, neurological sequelae of SARS-CoV-2 infection have already been reported and highlight the relevance of considering the neurological impact of coronavirus from a translational perspective. Animal models of SARS and Middle East respiratory syndrome (MERS), caused by structurally similar coronaviruses during the 2002 and 2012 epidemics, have provided valuable data on nervous system involvement by coronaviruses and the potential for CNS spread of SARS-CoV-2. One key finding that may unify these pathogens is that all require angiotensin-converting enzyme 2 (ACE2) as a cell entry receptor. The CoV spike glycoprotein, by which SARS_CoV-2 binds to cell membranes, binds ACE2 with a higher affinity compared to SARS-CoV. The expression of this receptor in neurons and endothelial cells hints that SARS-CoV-2 may have higher neuroinvasive potential compared to previous coronaviruses. Yet, how such invasiveness might contribute to respiratory failure or cause direct neurological damage remains to be determined. Both direct and indirect mechanisms may be of relevance. Clinical heterogeneity potentially driven by differential host immune-mediated responses will require extensive investigation. Development of disease models to anticipate emerging neurological complications and to explore mechanisms of direct or immune-mediated pathogenicity in the short- and medium- term is therefore of great importance. In this brief review, we describe the current knowledge from models of previous coronavirus infections and discuss their potential relevance to COVID-19."],"journal":"Eur J Neurol","authors":["Natoli, Silvia","Oliveira, Vanessa","Calabresi, Paolo","Maia, Luis F","Pisani, Antonio"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333487","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/ene.14277","keywords":["covid-19","sars-cov-2","animal models","coronavirus","neurotropism","systematic review","viral infections"],"topics":["Mechanism"],"weight":1,"_version_":1666138493959536640,"score":241.76588},{"pmid":32487714,"title":"Cranial Neuropathies and COVID-19: Neurotropism and Autoimmunity.","text":["Cranial Neuropathies and COVID-19: Neurotropism and Autoimmunity.","The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or \"COVID-19\" global pandemic began in late 2019. Like its predecessors, SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), COVID-19 binds to angiotension converting enzyme 2 (ACE2) receptors to facilitate tissue invasion, and potentially gain entry into the nervous system.(1) This single-stranded RNA virus shares 75-80% identical genome sequence with MERS-CoV and SARS-CoV, but has increased virulence, persistence, and lethality.(2) Amid catastrophic human suffering, severe neurological complications of COVID-19 have been identified; yet, subtle neurological manifestations have likely been under-reported.","Neurology","Costello, Fiona","Dalakas, Marinos C","32487714"],"abstract":["The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or \"COVID-19\" global pandemic began in late 2019. Like its predecessors, SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), COVID-19 binds to angiotension converting enzyme 2 (ACE2) receptors to facilitate tissue invasion, and potentially gain entry into the nervous system.(1) This single-stranded RNA virus shares 75-80% identical genome sequence with MERS-CoV and SARS-CoV, but has increased virulence, persistence, and lethality.(2) Amid catastrophic human suffering, severe neurological complications of COVID-19 have been identified; yet, subtle neurological manifestations have likely been under-reported."],"journal":"Neurology","authors":["Costello, Fiona","Dalakas, Marinos C"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32487714","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1212/WNL.0000000000009921","topics":["Mechanism","Diagnosis"],"weight":1,"_version_":1668892169378725888,"score":236.08762},{"pmid":32167747,"pmcid":"PMC7094171","title":"Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms.","text":["Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms.","The recent outbreak of coronavirus infectious disease 2019 (COVID-19) has gripped the world with apprehension and has evoked a scare of epic proportion regarding its potential to spread and infect humans worldwide. As we are in the midst of an ongoing pandemic of COVID-19, scientists are struggling to understand how it resembles and differs from the severe acute respiratory syndrome coronavirus (SARS-CoV) at the genomic and transcriptomic level. In a short time following the outbreak, it has been shown that, similar to SARS-CoV, COVID-19 virus exploits the angiotensin-converting enzyme 2 (ACE2) receptor to gain entry inside the cells. This finding raises the curiosity of investigating the expression of ACE2 in neurological tissue and determining the possible contribution of neurological tissue damage to the morbidity and mortality caused by COIVD-19. Here, we investigate the density of the expression levels of ACE2 in the CNS, the host-virus interaction and relate it to the pathogenesis and complications seen in the recent cases resulting from the COVID-19 outbreak. Also, we debate the need for a model for staging COVID-19 based on neurological tissue involvement.","ACS Chem Neurosci","Baig, Abdul Mannan","Khaleeq, Areeba","Ali, Usman","Syeda, Hira","32167747"],"abstract":["The recent outbreak of coronavirus infectious disease 2019 (COVID-19) has gripped the world with apprehension and has evoked a scare of epic proportion regarding its potential to spread and infect humans worldwide. As we are in the midst of an ongoing pandemic of COVID-19, scientists are struggling to understand how it resembles and differs from the severe acute respiratory syndrome coronavirus (SARS-CoV) at the genomic and transcriptomic level. In a short time following the outbreak, it has been shown that, similar to SARS-CoV, COVID-19 virus exploits the angiotensin-converting enzyme 2 (ACE2) receptor to gain entry inside the cells. This finding raises the curiosity of investigating the expression of ACE2 in neurological tissue and determining the possible contribution of neurological tissue damage to the morbidity and mortality caused by COIVD-19. Here, we investigate the density of the expression levels of ACE2 in the CNS, the host-virus interaction and relate it to the pathogenesis and complications seen in the recent cases resulting from the COVID-19 outbreak. Also, we debate the need for a model for staging COVID-19 based on neurological tissue involvement."],"journal":"ACS Chem Neurosci","authors":["Baig, Abdul Mannan","Khaleeq, Areeba","Ali, Usman","Syeda, Hira"],"date":"2020-03-14T11:00:00Z","year":2020,"_id":"32167747","source":"PubMed","week":"202011|Mar 09 - Mar 15","doi":"10.1021/acschemneuro.0c00122","keywords":["ace2 tissue distribution","covid-19","coronavirus","sars-cov-2","host-virus interaction","spike protein"],"link_comment_in":"32233443","topics":["Mechanism"],"weight":1,"_version_":1666138490636599296,"score":231.90129},{"pmid":32469387,"title":"Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review.","text":["Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review.","Importance: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019, causing human coronavirus disease 2019 (COVID-19), which has now spread into a worldwide pandemic. The pulmonary manifestations of COVID-19 have been well described in the literature. Two similar human coronaviruses that cause Middle East respiratory syndrome (MERS-CoV) and severe acute respiratory syndrome (SARS-CoV-1) are known to cause disease in the central and peripheral nervous systems. Emerging evidence suggests COVID-19 has neurologic consequences as well. Observations: This review serves to summarize available information regarding coronaviruses in the nervous system, identify the potential tissue targets and routes of entry of SARS-CoV-2 into the central nervous system, and describe the range of clinical neurological complications that have been reported thus far in COVID-19 and their potential pathogenesis. Viral neuroinvasion may be achieved by several routes, including transsynaptic transfer across infected neurons, entry via the olfactory nerve, infection of vascular endothelium, or leukocyte migration across the blood-brain barrier. The most common neurologic complaints in COVID-19 are anosmia, ageusia, and headache, but other diseases, such as stroke, impairment of consciousness, seizure, and encephalopathy, have also been reported. Conclusions and Relevance: Recognition and understanding of the range of neurological disorders associated with COVID-19 may lead to improved clinical outcomes and better treatment algorithms. Further neuropathological studies will be crucial to understanding the pathogenesis of the disease in the central nervous system, and longitudinal neurologic and cognitive assessment of individuals after recovery from COVID-19 will be crucial to understand the natural history of COVID-19 in the central nervous system and monitor for any long-term neurologic sequelae.","JAMA Neurol","Zubair, Adeel S","McAlpine, Lindsay S","Gardin, Tova","Farhadian, Shelli","Kuruvilla, Deena E","Spudich, Serena","32469387"],"abstract":["Importance: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019, causing human coronavirus disease 2019 (COVID-19), which has now spread into a worldwide pandemic. The pulmonary manifestations of COVID-19 have been well described in the literature. Two similar human coronaviruses that cause Middle East respiratory syndrome (MERS-CoV) and severe acute respiratory syndrome (SARS-CoV-1) are known to cause disease in the central and peripheral nervous systems. Emerging evidence suggests COVID-19 has neurologic consequences as well. Observations: This review serves to summarize available information regarding coronaviruses in the nervous system, identify the potential tissue targets and routes of entry of SARS-CoV-2 into the central nervous system, and describe the range of clinical neurological complications that have been reported thus far in COVID-19 and their potential pathogenesis. Viral neuroinvasion may be achieved by several routes, including transsynaptic transfer across infected neurons, entry via the olfactory nerve, infection of vascular endothelium, or leukocyte migration across the blood-brain barrier. The most common neurologic complaints in COVID-19 are anosmia, ageusia, and headache, but other diseases, such as stroke, impairment of consciousness, seizure, and encephalopathy, have also been reported. Conclusions and Relevance: Recognition and understanding of the range of neurological disorders associated with COVID-19 may lead to improved clinical outcomes and better treatment algorithms. Further neuropathological studies will be crucial to understanding the pathogenesis of the disease in the central nervous system, and longitudinal neurologic and cognitive assessment of individuals after recovery from COVID-19 will be crucial to understand the natural history of COVID-19 in the central nervous system and monitor for any long-term neurologic sequelae."],"journal":"JAMA Neurol","authors":["Zubair, Adeel S","McAlpine, Lindsay S","Gardin, Tova","Farhadian, Shelli","Kuruvilla, Deena E","Spudich, Serena"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32469387","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1001/jamaneurol.2020.2065","topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1668167109909151746,"score":226.34299}]}